Results 21 to 30 of about 47,533 (300)

WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]

Scientific Reports, 2017
AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Dongmei Yan, Linglan Tu, Haining Yuan, Jianfei Fang, Liyan Cheng, Xiaoliang Zheng, Xiaoju Wang   +6 more
openalex   +3 more sources

Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [PDF]

Int J Mol Med
Lai C, Jia X, Chen Y, Chen K, Wang F, Zhang Q, Xiang X, Chen ZS, Xu L, Dai S.   +9 more
europepmc   +2 more sources

Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation [PDF]

Cell Death and Disease
Cancer-associated fibroblasts (CAFs) play a key role in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). However, the potential mechanisms by which CAFs promote chemotherapy resistance have not yet been explored. In this study, we found
Rihua He, Chonghui Hu, Yuan Yuan, Tingting Li, Qing Tian, Tianhao Huang, Qing Lin, Shangyou Zheng, Chujie Chen, Zhiqiang Fu, Rufu Chen   +10 more
doaj   +2 more sources

Endothelin-1 Mediates Oxaliplatin Resistance via Activation of YAP Signaling in Colorectal Cancer. [PDF]

Oncol Res
Yang R, Yuan D, Liang C, Zhu S, Huang J, Zhang Y, He W, Li Q, Zhang H.   +8 more
europepmc   +3 more sources

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype. [PDF]

Cell Death Dis
Wong SQR, Das M, Tenzin K, Shirgaonkar N, Chua H, Chee LX, Sae Yeoh A, Murugiah AA, Chua WY, Theardy MS, Subel EJ, Thangavelu MT, Chan JV, Yap CK, Tan IBH, Tsantoulis P, Tejpar S, Loo JM, DasGupta R.   +18 more
europepmc   +3 more sources

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. [PDF]

BMC Gastroenterol
Liao X, Liu M, Hong C, Liu Y, Li Q, Chen Y, Zhang T, Chen H, Fu S.   +8 more
europepmc   +3 more sources

TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability [PDF]

Cell Death & Disease, 2020
Abstract Resistance to chemotherapy remains the major cause of treatment failure in patients with colorectal cancer (CRC). Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC. The level of TRIM25 in OXA-resistant patients who experienced recurrence during the follow-up period was significantly ...
Sha Zhou, Jianhong Peng, Liuniu Xiao, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Mengzhong Liu, Zhizhong Pan, Zhenlin Hou   +9 more
openalex   +6 more sources

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. [PDF]

Front Cell Dev Biol
Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y, Zhang C.   +14 more
europepmc   +3 more sources

Oxaliplatin-resistant colorectal cancer models for nanoparticle hyperthermia [PDF]

International Journal of Hyperthermia, 2021
Metastatic colorectal cancer (CRC) is complicated by chemotherapy-resistant cell populations. Oxaliplatin is used in heated intraperitoneal hyperthermic chemoperfusion (HIPEC) for treatment of disseminated CRC. Photothermal nanoparticles can provide focal heating to improve the response of CRC cells to oxaliplatin, by confining heating near individual ...
Bryce McCarthy, Ravi Singh, Nicole Levi-Polyachenko   +2 more
openaire   +3 more sources

JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis

Acta Biochimica et Biophysica Sinica, 2023
Currently, platinum-containing regimens are the most commonly used regimens for advanced gastric cancer patients, and chemotherapy resistance is one of the main reasons for treatment failure.
Li Suyao, Wei Yichou, Sun Xun, Liu Mengling, Zhu Mengxuan, Yuan Yitao, Zhang Jiayu, Dong Yu, Hu Keshu, Ma Sining, Zhang Xiuping, Xu Bei, Jiang Hesheng, Gan Lu, Liu Tianshu   +14 more
doaj   +1 more source